WO2005086835A3 - Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics - Google Patents

Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics Download PDF

Info

Publication number
WO2005086835A3
WO2005086835A3 PCT/US2005/007666 US2005007666W WO2005086835A3 WO 2005086835 A3 WO2005086835 A3 WO 2005086835A3 US 2005007666 W US2005007666 W US 2005007666W WO 2005086835 A3 WO2005086835 A3 WO 2005086835A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
aptamers
autoimmune disease
methods
cytokine family
Prior art date
Application number
PCT/US2005/007666
Other languages
French (fr)
Other versions
WO2005086835A2 (en
Inventor
John L Diener
Alicia Ferguson
Nobuko Hamaguchi
Sara Chesworth Keene
H A Daniel Lagasse
Pooja Sawhney
Kristin Thompson
Original Assignee
Archemix Corp
John L Diener
Alicia Ferguson
Nobuko Hamaguchi
Sara Chesworth Keene
H A Daniel Lagasse
Pooja Sawhney
Kristin Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp, John L Diener, Alicia Ferguson, Nobuko Hamaguchi, Sara Chesworth Keene, H A Daniel Lagasse, Pooja Sawhney, Kristin Thompson filed Critical Archemix Corp
Priority to RU2006135119/04A priority Critical patent/RU2006135119A/en
Priority to CA002557633A priority patent/CA2557633A1/en
Priority to JP2007502114A priority patent/JP2007527246A/en
Priority to MXPA06010012A priority patent/MXPA06010012A/en
Priority to EP05732056A priority patent/EP1756138A4/en
Priority to AU2005220910A priority patent/AU2005220910A1/en
Priority to BRPI0508363-0A priority patent/BRPI0508363A/en
Publication of WO2005086835A2 publication Critical patent/WO2005086835A2/en
Priority to IL177744A priority patent/IL177744A0/en
Priority to TNP2006000265A priority patent/TNSN06265A1/en
Publication of WO2005086835A3 publication Critical patent/WO2005086835A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Abstract

The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.
PCT/US2005/007666 2004-03-05 2005-03-07 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics WO2005086835A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU2006135119/04A RU2006135119A (en) 2004-03-05 2005-03-07 APTAMERS TO THE HUMAN IL-12 CYTOKINE FAMILY AND THEIR APPLICATION AS MEDICINES FOR AUTOIMMUNE DISEASES
CA002557633A CA2557633A1 (en) 2004-03-05 2005-03-07 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
JP2007502114A JP2007527246A (en) 2004-03-05 2005-03-07 Aptamers against the human IL-12 cytokine family and their use as therapeutics for autoimmune diseases
MXPA06010012A MXPA06010012A (en) 2004-03-05 2005-03-07 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics.
EP05732056A EP1756138A4 (en) 2004-03-05 2005-03-07 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
AU2005220910A AU2005220910A1 (en) 2004-03-05 2005-03-07 Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
BRPI0508363-0A BRPI0508363A (en) 2004-03-05 2005-03-07 aptamers for the human il-12 cytokine family and their use as an autoimmune disease therapy
IL177744A IL177744A0 (en) 2004-03-05 2006-08-29 Aptamers and pharmaceutical compositions containing the same
TNP2006000265A TNSN06265A1 (en) 2004-09-07 2006-09-04 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55096204P 2004-03-05 2004-03-05
US60/550,962 2004-03-05
US60804604P 2004-09-07 2004-09-07
US60/608,046 2004-09-07

Publications (2)

Publication Number Publication Date
WO2005086835A2 WO2005086835A2 (en) 2005-09-22
WO2005086835A3 true WO2005086835A3 (en) 2006-12-21

Family

ID=34976179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/007666 WO2005086835A2 (en) 2004-03-05 2005-03-07 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics

Country Status (12)

Country Link
US (2) US20070066550A1 (en)
EP (1) EP1756138A4 (en)
JP (1) JP2007527246A (en)
AU (1) AU2005220910A1 (en)
BR (1) BRPI0508363A (en)
CA (1) CA2557633A1 (en)
EC (1) ECSP066907A (en)
IL (1) IL177744A0 (en)
MA (1) MA28969B1 (en)
MX (1) MXPA06010012A (en)
RU (1) RU2006135119A (en)
WO (1) WO2005086835A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
PL1794174T3 (en) 2004-09-01 2012-11-30 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity
KR100911624B1 (en) * 2007-05-14 2009-08-12 연세대학교 산학협력단 Methods for Effectively Coexpressing ????? and ?????
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
ES2602119T3 (en) 2008-07-14 2017-02-17 The University Of Tokyo Aptámero against IL-17 and use of the same
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
KR101810593B1 (en) 2010-06-16 2017-12-22 다이나박스 테크놀로지 코퍼레이션 Methods of treatment using tlr7 and/or tlr9 inhibitors
JP6041288B2 (en) * 2012-02-13 2016-12-07 国立大学法人山口大学 Phospholamban target modified RNA aptamer
JP6591392B2 (en) * 2013-03-14 2019-10-16 ソマロジック, インコーポレイテッドSomaLogic, Inc. Aptamers that bind to IL-6 and their use in the treatment or diagnosis of IL-6 mediated conditions
US9850492B2 (en) 2013-03-22 2017-12-26 The University Of Tokyo Aptamer to IL-17 and use thereof
CN106456542A (en) * 2014-03-17 2017-02-22 葛兰素史密斯克莱知识产权发展有限公司 Aptamers for topical delivery
MX2018003376A (en) 2015-09-17 2018-08-15 Amgen Inc Prediction of clinical response to il23-antagonists using il23 pathway biomarkers.
CA3007098A1 (en) 2015-12-22 2017-06-29 Amgen Inc Ccl20 as a predictor of clinical response to il23-antagonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6610285B1 (en) * 1998-04-14 2003-08-26 Chugai Seiyaku Kabushiki Kaisha Cytokine-like proteins that promote cell proliferation
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4959309A (en) * 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0229046B1 (en) * 1985-03-30 1994-05-04 BALLIVET, Marc Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
CA2084987C (en) * 1990-06-11 2007-02-13 Larry Gold Nucleic acid ligands
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
DE552178T1 (en) * 1990-10-12 1994-02-03 Max Planck Gesellschaft MODIFIED RIBOZYMS.
WO1992014843A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5338671A (en) * 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5817635A (en) * 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
EP1741780A3 (en) * 1995-06-02 2007-03-28 Gilead Sciences, Inc. High affinity oligonucleotide ligands to growth factors
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
JPH11507529A (en) * 1995-06-07 1999-07-06 ネクスター ファーマスーティカルズ，インコーポレイテッド High affinity nucleic acid ligands for cytokines
US5852191A (en) * 1995-06-07 1998-12-22 Carnegie Mellon University Rigidized monomethine cyanines
DK0833944T3 (en) * 1995-06-07 2009-05-11 Gilead Sciences Inc Nucleic acid ligands that bind to and inhibit DNA polymerases
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP1009413B1 (en) * 1997-09-05 2007-02-14 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or treating asthma
US5958694A (en) * 1997-10-16 1999-09-28 Caliper Technologies Corp. Apparatus and methods for sequencing nucleic acids in microfluidic systems
CA2329252A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP4358428B2 (en) * 2000-11-01 2009-11-04 東洋エンジニアリング株式会社 Urea production method
JP2006516151A (en) * 2002-11-21 2006-06-22 アーケミックス コーポレイション Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods for their preparation and use
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
AU2004219625B9 (en) * 2003-03-10 2010-12-23 Merck Sharp & Dohme Corp. Uses of IL-23 agonists and antagonists; related reagents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6610285B1 (en) * 1998-04-14 2003-08-26 Chugai Seiyaku Kabushiki Kaisha Cytokine-like proteins that promote cell proliferation
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURGSTALLER P. ET AL.: "Aptamers and Aptazymes: Accelerating Small Molecule Drug Discovery", CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 5, 2002, pages 690 - 700, XP009032914 *
CORDOBA-RODRIQUEZ R. ET AL.: "IL-23 and IL-27: New Members of the Growing Family of IL-12-Related Cytokines with Important Implications for Therapeutics", vol. 3, 2003, pages 715 - 723, XP009048344 *
DATABASE GENBANK [online] 26 September 1999 (1999-09-26), XP003004964, Database accession no. (AF180563) *
DATABASE GENBANK [online] XP003004963, Database accession no. (NM_016584) *
VANDENBROECK ET AL.: "Inhibiting Cytokines of the Interleukin-12 Family: Recent Advances and Novel Challenges", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 56, 2004, pages 145 - 160, XP008074541 *

Also Published As

Publication number Publication date
CA2557633A1 (en) 2005-09-22
US20090082555A1 (en) 2009-03-26
EP1756138A4 (en) 2009-07-01
JP2007527246A (en) 2007-09-27
RU2006135119A (en) 2008-04-10
US20070066550A1 (en) 2007-03-22
AU2005220910A1 (en) 2005-09-22
WO2005086835A2 (en) 2005-09-22
ECSP066907A (en) 2006-12-20
IL177744A0 (en) 2007-07-04
MA28969B1 (en) 2007-11-01
EP1756138A2 (en) 2007-02-28
MXPA06010012A (en) 2007-03-23
BRPI0508363A (en) 2007-07-24

Similar Documents

Publication Publication Date Title
WO2007035922A3 (en) Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
WO2005086835A3 (en) Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
WO2008065378A3 (en) Binding members for interleukin-6
PL1615952T3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003083041A8 (en) Cripto-specific antibodies
DE69929232D1 (en) VIRUSELY PARTICLES FOR INDUCING AUTOANTIC BODIES
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
EA201000424A1 (en) ANTIBODIES TO IL-23
WO2005078124A3 (en) Diagnostic marker for cancer
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
EA200602137A1 (en) HYDROGEL PREPARATIONS OF INTERFERON
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
MX2021002605A (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer.
IL169367A0 (en) Defensin proteins
GB0418388D0 (en) Cell therapy
TW200724679A (en) Treatment of disease using an improved regulated expression system
TNSN06265A1 (en) Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
EA200700346A1 (en) BACTERIOPHAG- AND PROFAG-SPECIFIC PROTEINS IN CANCER GENETIC THERAPY
WO2004093820A3 (en) Methods and compositions for solid tumor treatment
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2557633

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 177744

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 549579

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/010012

Country of ref document: MX

Ref document number: 12006501723

Country of ref document: PH

Ref document number: 2007502114

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 5569/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/07983

Country of ref document: ZA

Ref document number: 200607983

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005220910

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067020628

Country of ref document: KR

Ref document number: 2005732056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 06100210

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006135119

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005220910

Country of ref document: AU

Date of ref document: 20050307

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005220910

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580014470.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005732056

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067020628

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0508363

Country of ref document: BR